BDP China 2020 Bro€¦ · Yin Nan Po Director, Asia Supply Chain, Amgen, China NEW John Zhang Vice...

www.biopharmaproduction.com

Knowledge Partners:

19–20 MAY 2020Hilton Shanghai Hongqiao, China

Brought to you by:

30+NEW SPEAKERS IN 2020

InteractiveSESSION FORMATS

Start up &TECH COLLABORATION ZONE

The BDPPARTY

VIP Access PASS FOR PHARMA & BIOTECH

VIEW THE AGENDA

VIEW THE AGENDA

VIEW THE AGENDA

Special 1-for-1 Offer for China Pharmaceutical &

Biotech Companies*



CHINA & GLOBAL BIOPHARMA EXPERTSDr. Song RulinExecutive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

NEWMagnus BodinDirector Market Access, Biogen Biosimilars, Switzerland

NEW

Lisa ZhengExecutive Director, Cell Line Development, Transcenta, China

NEW

Yin Nan PoDirector, Asia Supply Chain, Amgen, China

NEW

John ZhangVice President, Manufacturing Technology and Process Development, BeiGene, China

NEW

Dr. Chris ChenChief Executive Officer, WuXi Biologics, China

NEW

Li Jing RongSenior Vice President, Product Development and Manufacturing, CStone Pharmaceuticals, China

NEW

Zhang Zhe RuPresident, Head of CMC and Manufacturing, I-MAB Biopharma, China

Dr. Zhu JianweiProfessor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China

NEW

Dr. Kerstin OtteProfessor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany

NEWYi JizuSenior Vice President, CMC & Quality Operations, YZY Biopharma, China

NEW

Liu XunPresident, Biomedicine Development and Business Division, Jiangsu Hengrui Medicine, China

NEW

Dr. Orit Aharonovitz Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, Israel

NEW

Dr. Bruce HeExecutive Director, Research and Development, Shanghai Henlius Biotech, China

NEW

Jerry SuChief Executive Officer, Zhejiang Huahai Biopharmaceuticals

NEW

Xi ChenDirector, Cell Engineering, Qilu Pharmaceuticals, China

NEW

Ma Yuan HuiExecutive Director, Preclinical Science, Shanghai HaiHe Pharmaceutical, China

NEWDr. Sanjeev HedgeAssociate Vice President, Global Clinical Operations, Mylan, India

NEW

Dr. Allen HoSenior Director, Regulatory Technical CMC, JHL Biotech Inc, China

David ShaoPresident, Chief Executive Officer, Yisheng Biopharma, China

NEW

Glenn HassanChief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China

NEWWu You LingChief Executive Officer, Zhejiang Teruisi Pharmaceuticals, China

Dennis TanManager, Quality Assurance, Tanvex Biopharma, Taiwan

Dr. Pan ZhiweiSenior Director, Process Development, Junshi Pharma, China

Frank YeSenior Vice President, Technical Operations, Transcenta, China

Rani JarkasChairman, Cedrus Investments, Hong Kong

NEW

Liang TangVice President, CMC Management, WuXi Biologics, China

NEW

Dr. Song ZhiweiPrincipal Scientist, Bioprocessing Technology Institute, Singapore

Eric ChangHead, Cell Line Development, JHL Biotech, China

Fu WeiChief Executive Officer, CBC Group, China

Bao CaiSenior Director, Manufacturing, Bio-Thera Solutions, China

NEW

Dr. Karen LiuFounding Partner, 3E Bioventures Capital, China

NEWNEW



CONFERENCE AGENDA

08.00 Conference Registration & Morning Coffee

PLENARY SESSIONS

09.00 Chairperson’s Opening Remarks

09.10 OPENING ADDRESS China’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

09.30 KEYNOTE ADDRESS China’s Biological Facilities for the Future – WuXi’s Story on Technology and Innovation Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

09.50 Manufacturers’ Panel:New Therapies, New Tech and New Investments• New frontiers in drug development • What is the gap in quality and investment?• Embracing new tech and start-ups to drive progress • New therapeutics manufacturing, commercialisation

and global access• Biomanufacturing 4.0 – Where are we at? • DAL’s GAMP and licencing laws – How is it affecting

our business and what we can expect? • The GQCE framework – quality consistency and

better pricing

Panelists: Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals Co., China Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, ChinaMore panellists to be confirmed

10.30 Morning Networking & Refreshment Break

9th Annual Cell Line Development & Engineering Asia Commences

11.00 Chairperson’s Opening Remarks Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, Israel

THE STATE-OF-PLAY FOR CLD

11.10 OPENING KEYNOTE Optimising Cell Line Development: Applications for Furthering Biopharma R&D Strategy Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, Israel

11.40 Enhancing Complex Protein Expression with Highly-Efficient Gene Integration TechnologySenior Representative from Lonza

12.10 Networking Lunch

NOVEL ADVANCES IN CLD TECHNIQUES & TECHNOLOGY

13.10 Novel Transposases in Accelerating Cell Line Development Dr. Claes Gustafsson, Chief Commercial Officer and Co-Founder, ATUM, U.S.

13.40 Efficient Cell Lines and Technology Applications Lisa Zheng, Executive Director, Cell Line Development, Transcenta, China

14.10 Developing a New CLD Process from Ground-Up Mark Stockdale, Amalgamator of Business and Biology, Solentim, U.K.

14.40 Whole-Genome Sequencing with Bioinformatics Tools for CHO Cell Lines Senior Representative from Selexis

15.10 Afternoon Networking Break & Tea

15.40 High-Throughput Cloning Screening and Performance for Next-Generation Innovative TherapeuticsTing Chen, Director, Alphamab Oncology, China

16.10 Precise Cell Processing and Workflow Automation in CLDSenior Representative from Berkeley Lights

16.40 Industry Panel: Utilising Platform Technologies for CLD

Panelists: Dr. Orit Aharonovitz, Senior Director, Cell Line & Process Development, Teva Pharmaceuticals, Israel

Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, China Eric Chang, Head, Cell Line Development, JHL Biotech, China Lisa Zheng, Executive Director, Cell Line Development, Transcenta, China

17.20 End of Conference Day 1

DAY 1, TUESDAY 19 MAY 2020 JOINT PLENARY SESSIONS


09.10 KEYNOTE ADDRESS China’s Biopharma Capital Markets – Future Funds and Innovative FinancingFu Wei, Chief Executive Officer, CBC Group, China

09.40 Venture Capitals’ Roundtable: Show Me the Drug• Investment landscape in the Chinese biopharma

market • Evaluating drug pipelines and development prospects • Mergers, expansion and JVs – Where do we see

transactions picking up? • Financing new plants, new therapeutics, product

launch and scaling-up operations – How do we review?

• Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Panelists: Rani Jarkas, Chairman, Cedrus Investments, Hong Kong Judith Li, Partner, Lilly Asia Ventures, China Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China Lynn Yang, Managing Director, Sequoia Capital, China Dr. John Zhu, Partner, 6 Dimensions Capital, China


9th Annual Cell Line Development & Engineering Asia Resumes

10.50 Chairperson’s Opening Remarks Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

ENGINEERING HOST CELL LINES, GENOMICS & CRISPR IN FOCUS

11.00 Advances in Glycosylation and Expression Vectors for Recombinant Proteins Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

11:10 Applications for Glycan Analysis Workflows and Bioanalytical ProteinsSenior Representative from ProZyme

11.40 CRISPR in Cell Line Development: Applications of CRISPR in Rapid Development of Stable Transgene CHO Cell Lines Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China

12:30 Networking Lunch

13.30 Next-Generation Cell Line Engineering for Biopharmaceutical Production Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany

OPTIMISING WORKFLOWS AND BIOPROCESSES

14.00 Integrated Cell Line Development Strategy in Whole CMC Picture

Xi Chen, Director, Cell Engineering, Qilu Pharmaceuticals, China

14.30 Exploring the Synergies between Engineered Host Cells and Process DevelopmentEric Chang, Head, Cell Line Development, JHL Biotech, China

15.00 Panel Discussion: What’s Next in the Future of CLD&E

Panelists: Dr. Zhu Jianwei, Professor and Director of MOE Engineering Research Center of Cell Engineering and Antibody, Shanghai Jiaotong University; CEO and Chief Scientist, Jecho Biopharmaceuticals, China Dr. Kerstin Otte, Professor, Institute of Applied Biotechnology, Biberach University of Applied Sciences, Germany Dr. Song Zhiwei, Principal Scientist, Bioprocessing Technology Institute, Singapore

15.40 Afternoon Networking & Refreshment Break

16.10 Outsourcing and Insourcing of CLD: End-User Perspectives and Commercial ROISenior Representative from TOT Biopharma, China

16.40 A Fully-Integrated Platform Approach for Highly-Quality CLD Senior Representative from Shanghai Henlius Biotech, China

17.10 Accelerating CLD for Commercial Success Dr. Pan Zhiwei, Senior Director, Process Development, Junshi Pharma, China


DAY 2, WEDNESDAY 20 MAY 2020

*Please note that conference agenda and timing are subjected to change according to market development.



CONFERENCE AGENDA

11.40 Impact of CNDA Reform on CMC Strategy at IND Stage Dr. Ma Yuan Hui, Executive Director, Preclinical Science, Shanghai HaiHe Pharmaceutical, China


BIOMANUFACTURING 2030 – CHINA’S GREAT LEAP

13.10 Trends in Pharma 4.0 Standards and China’s New Drug Delivery Strategy Dr. Liu Xun, President, Biomedicine Development and Business Division, Jiangsu Hengrui Medicine, China

13.40 Debottlenecking and Process Optimisation in China BioPharma Landscape Dr. Simon Hsu, Senior Vice President, Technical Operations, Henlius, China

14.10 China’s Cell and Gene Therapy Market: Manufacturing CAR-T Cell Therapy Products – Technology Acquisition in Bioprocess Development while Building Independent R&D Capability Dr. Richard Wang, Chief Executive Officer, Fosun Kite Biotechnology, China

14.40 PANEL DISCUSSION Cell and Gene Therapy Manufacturing – Regulation, Investment and Commercialisation

Panellists:Senior representative, LonzaMore panelists to be confirmed


15.40 The New Age of Smart Continuous Manufacturing as Market Moves to Commercial Dr. Li Jing Rong, Senior Vice President, Product Development and Manufacturing, CStone Pharmaceuticals, China

16.40 Scaling Up the Commercial Production of mAb Therapeutics in China Dr. Wu You Ling, Chief Executive Officer, Zhejiang Teruisi Pharmaceuticals, China

17.10 WuXi “Factory of the Future” – A CMC Manufacturing Case Study Dr. Liang Tang, Vice President, CMC Management, WuXi Biologics, China


The BDP Party

DAY 1, TUESDAY 19 MAY 2020 DAY 2, WEDNESDAY 20 MAY 202008.00 Conference Registration & Morning Coffee

PLENARY SESSIONS


09.10 OPENING ADDRESS China’s Big Leap towards BioPharma 2030 – Innovation, Industrialization, Internationalization Dr. Song Rulin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

09.30 KEYNOTE ADDRESS China’s Biologics Facilities for the Future – WuXi’s Story on Technology and Innovation Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

09.50 Manufacturers’ Panel:New Therapies, New Tech and New Investment• New frontiers in drug development• What is the gap in quality and investment?• Embracing new tech and start-ups to drive progress• New therapeutics manufacturing, commercialization

and global access• Biomanufacturing 4.0 – Where are we at?• DAL’s GAMP and licensing laws – How is it affecting

our business and what can we expect?• The GQCE framework – Quality consistency and

better pricing

Panelists: Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, China


10th Annual Biomanufacturing commences


GMP IMPLEMENTATION – THE MADE IN CHINA 2025 PLAN

11.10 Under Chinese New Drug Administration Law and New Vaccine Law – Oversight and Implementation on Commercial Bioprocess Development and Process Performance Qualification Dr. John Zeng, Executive Vice President, Product Development and Commercialization, Shanghai Zerun Biotechnology, China


INNOVATIVE BIOPROCESS DEVELOPMENT

13.30 Glycosylation of Monoclonal Antibody and the Manipulation Liu Dong Lian, Vice President, Manufacturing, TOT Biopharma, China

14.00 Process Intensification for mAb Purification – Upfront Removal of HCP & HCD and Use of Protein A Resin with High Selectivity Dr. Bjorn Hammarberg, Business Development Asia, Bio-Works, Sweden

14.30 China’s Biological Facilities for The Future – Growth, Innovation and Investments Larry Zhang, Chief Executive Officer, CASI Pharmaceuticals. China

15.00 Vaccine Manufacturing Innovation Dr. David Shao, President, Chief Executive Officer, Yisheng Biopharma, China


QUALITY MANAGEMENT & EFFICACY STANDARDS

16.00 Integrated CMC Platforms to Develop Robust Downstream Process for Clinical Manufacturing Dr. Zhang Zhe Ru, President, Head of CMC and Manufacturing, I-MAB Biopharma, China

16.30 Ensure Uninterrupted Supply of Biological DrugsYin Nan Po, Director, Asia Supply Chain, Amgen, China

17.00 Biopharma Quality Assurance Best Practices and PAT Insights Dr. Yi Jizu, Senior Vice President, CMC and Quality Operations, YZY Biopharma, China

17.30 Biomanufacturing Process Validation and Quality Risk Management Bao Cai, Senior Director, Manufacturing, Bio-Thera Solutions, China


08.00 Morning Coffee

PLENARY SESSIONS


09.10 Keynote Address: China’s Biopharma Capital Markets – Future Funds and Innovative FinancingFu Wei, Chief Executive Officer, CBC Group, China


market• Evaluating drug pipelines and development prospects• Mergers, expansion and JVs – Where do we see

transactions picking up?• Financing new plants, new therapeutics, product



Panelists: Rani Jarkas, Chairman, Cedrus Investments, Hong KongJudith Li, Partner, Lilly Asia Ventures, China Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, ChinaLynn Yang, Managing Director, Sequoia Capital, ChinaDr. John Zhu, Partner, 6 Dimensions Capital, China


10th Annual Biomanufacturing resumes


FUTURE FACILITIES & SMART BIOMANUFACTURING

11.00 Manufacturing Technology Showcases – Improving Cost and Efficiency Frank Ye, Senior Vice President, Technical Operations, Transcenta, China

11.30 Manufacturing Technology – From Tech Transfer to Risk Analysis and Migration Strategy Dr. John Zhang, Vice President, Manufacturing Technology and Process Development, BeiGene, China

12.00 Tech Transfer Development for mAb Manufacturing Productivity Optimization Dr. Zack Zheng, Vice President, Process Development, JHL Biotech, China




CONFERENCE AGENDA

13:30 Case Study: Quality Control and Cost-effective Manufacturing of Biosimilars Nicholas Dukwon Kang, Global Quality Management Team Lead, GC Pharma, Korea

MARKET ACCESS, PATENT AND PRICING

13:45 Global and China Market Patent Expiry – Market Outlook, and Cost Savings Associated with Substituting For speaking opportunities, please contact [email protected]

14:15 Fireside Chat: Commercialisation of Biosimilars in China: Challenges and Opportunities

Dr. Wu You Ling, Chief Executive Officer, Zhejiang Teruisi Pharmaceuticals, China*

14:45 Afternoon Networking & Refreshment Break

15:15 Value-add Partnerships and Investments in the Chinese Biosimilars Market Senior Representative from select venture capital

15:45 Panel Discussion: Global and Regional Marketing Strategies- What worked and what didn’t • Product and brand differentiation between originators • How to overcome barriers to entry to the market• Go-to market strategies in the region • Working with local stakeholders for affordable

healthcare

16:30 End of Main Conference Day 1

13:40 China Biosimilars Manufacturers’ Panel: Moving Ahead with Product Innovation- Challenges and Opportunities • Ensuring quality differentiation between originators

and biosimilars • Considerations for innovation and meeting regional

and international regulatory requirements • Moving towards international product standards• Best practices and strategies to achieve high CMC

requirements

Panellists: Dr Jacqueline Liu, Vice President, TOT Biopharma, China Dr Sam Xie, Vice President, Research and Development, ZheJiang Teruisi Biopharmaceutical, China Dr Bruce He, Executive Director, Research and Development, Shanghai Henlius Biotech, China Bert Thomas, Senior Vice President, Business Development, Bio-Thera Solutions, Ltd, USA Magnus Bodin, Director Market Access, Biogen Biosimilars, Switzerland

14:20 Market Access and Commercialisation of Anti-TNF Biosimilars in Europe Magnus Bodin, Director Market Access, Biogen Biosimilars, Switzerland

CLINICAL TRIALS IN BIOSIMILARS

14:50 Pre-Clinical Considerations: Design Thinking for Quality Biosimilars Dr Sanjeev Hedge, Associate Vice President, Global Clinical Operations, Mylan, India

15:10 Afternoon Networking & Refreshment Break

15:40 Case Study: JHL’s Fast Track Strategy for CMC Approvals Dr. Allen Ho, Senior Director, Regulatory Technical CMC, JHL Biotech Inc, China

16:20 Managing Late-Stage Clinical Operations and Biosimilars Development

Dr Anup Choudhury, Associate Clinical Development Medical Director, Novartis, India

16:50 Panel Discussion: Maximising Successful Clinical Trials Operations and Lowering Costs • Managing drug development and pipelines • Balancing quality, cost and speed for biosimilars

developments • Utilising CMC data for speedier trials

Panellists: Dr Sanjeev Hedge, Associate Vice President, Global Clinical Operations, Mylan, India Dr. Allen Ho, Senior Director, Regulatory Technical CMC, JHL Biotech Inc, China Dr Anup Choudhury, Associate Clinical Development Medical Director, Novartis, India More panellists to be confirmed

17:30 Chairperson’s Summary and End of Main Conference Day 1

DAY 1, TUESDAY 19 MAY 2020 DAY 2, WEDNESDAY 20 MAY 202008.00 Main Conference Registration and Morning Coffee

PLENARY SESSIONS


09.10 Opening Address: China’s Big Leap towards BioPharma 2030– Innovation, Industrialization, Internationalization Dr. Song Rulin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

09.30 KEYNOTE ADDRESS China’s Biologics Facilities for the Future – WuXi’s Story on Technology and Innovation Dr. Chris Chen, Chief Executive Officer, WuXi Biologics, China

09.50 Manufacturers’ Panel:New Therapies, New Tech and New Investment• New frontiers in drug development• What is the gap in quality and investment?• Embracing new tech and start-ups to drive progress• New therapeutics manufacturing, commercialization

and global access• Biomanufacturing 4.0 – Where are we at?• DAL’s GAMP and licensing laws – How is it affecting

our business and what can we expect?• The GQCE framework – Quality consistency and

better pricing

Panelists: Jerry Su, Chief Executive Officer, Zhejiang Huahai Biopharmaceuticals, China

Glenn Hassan, Chief Finance Officer, Chief Business Officer, CANbridge Pharmaceuticals, ChinaMore panelists to be confirmed


11th Biosimilars Asia Commences

CHINA’S UPCOMING BIOSIMILARS

11:10 Chairperson’s Opening Remarks New Product Launches, International Standards and Global Market Access Dr Scott Liu, President and Chief Executive Officer, Shanghai Henlius Biotech, China

11:40 Touting the Manufacturing Strengths – TOT Biopharma’s Pipelines and Developments Dr Jacqueline Liu, Vice President, TOT Biopharma, China


13:10 Case Study of Bio-Thera’s pipelines and moving forward in the Chinese and Global Markets Bert Thomas, Senior Vice President, Business Development, Bio-Thera Solutions, Ltd, USA

PLENARY SESSIONS

09:00 Chairperson’s Opening Remarks

09.10 Keynote Address: China’s Biopharma Capital Markets – Future Funds and Innovative Financing

Fu Wei, Chief Executive Officer, CBC Group, China


market • Evaluating drug pipelines and development prospects • Mergers, expansion and JVs – Where do we see

transactions picking up? • Financing new plants, new therapeutics, product



Panelists: Rani Jarkas, Chairman, Cedrus Investments, Hong Kong Judith Li, Partner, Lilly Asia Ventures, China Dr. Karen Liu, Founding Partner, 3E Bioventures Capital, China Lynn Yang, Managing Director, Sequoia Capital, China Dr. John Zhu, Partner, 6 Dimensions Capital, China

10:20 Morning Networking and Refreshment Break

QUALITY, SAFETY AND EFFICACY

11:00 mAbs Case Study: Extractable & Leachable (E&L) Study for Single Use Manufacturing System (SUS) Michael H. Xie, Vice President, Analytics; Head, Bioassay and Analytical Development, Shanghai Henlius Biotech, USA

11:30 Proving Similarities for Biosimilars and Managing Product Variations For speaking opportunities, please contact [email protected]

12:00 Case Study: Maintaining High Quality, Safety and Efficacy of Biosimilars Dennis Tan, Manager, Quality Assurance, Tanvex Biopharma, Taiwan





EXHIBITORS:

MEDIA PARTNERS:

SPOTLIGHT SPONSOR:

SHOWCASE & PROFILE YOUR COMPANYThe Biopharma Production and Development (BDP) Week is your go-to event to reach out to key decision makers in the pharmaceutical industry.

Back for its 6th iteration, BDP Week in China enjoys unparalleled industry support. Known for generating knowledge, creating business opportunities, and bringing innovative ideas to the table, the 2-day event is a must attend!

To position your company as a market leader at this event and explore the range of branding and marketing opportunities available, please contact

Yvonne Leong to Tel: +65 6508 2489 l Email: [email protected]

BRONZE SPONSOR:

GOLD SPONSORS:

FLOOR PLAN

ENTRANCE

ENTRANCE

ENTRANCE

SPONSORSAND EXHIBITORS



With numerous shifts on the horizon, the Chinese biopharma industry approaches a tipping point as companies reevaluate current trends and strategies to achieve commercial excellence. The 6th Biopharma Development & Production Week 2020 will address the 2020 investment climate, technological advancements, industry case studies, and partnerships and expansion opportunities across key value chains.

With improved networking windows and elevated exhibition platforms, join us as the industry convenes at this highly anticipated annual gathering of biopharma leaders.

• Deep Dive Roundtables

• Innovation Think Tanks

• Process and Quality Solution Forums

• Integrated Conference and Show Floor

POSTER DISPLAY & PRESENTATIONShowcase your latest research developments and solutions at our BDP Poster Arena on the showfloor!

ENQUIRE NOW

BY INDUSTRY:

China/MNC Pharma & Biotech .................................................. 50%

CDMOs/CROs/CMOs ..................................................................... 25%

Tech Solution Providers .................................................................. 10%

Regulators, Healthcare Agencies & Associations ............... 5%

Scientific Research & Universities .............................................. 5%

Others ........................................................................................................ 5%

BY GEOGRAPHY:

China ........................................................................................................ 50%

Japan, Korea, HK, Taiwan ................................................................. 15%

Southeast Asia .................................................................................... 10%

USA ............................................................................................................ 10%

Europe ...................................................................................................... 10%

Other Region .......................................................................................... 5%

WHO WILL YOU MEET?

83000+ Unique

Pageviews

76 Countries

34000+ LinkedIn

Impressions

OURMARKETING ANDDIGITAL MEDIAOUTREACH

ABOUT THE EVENT

www.biopharmaproduction.comfile:///Users/imac/Library/Mail%20Downloads/Yvonne@[email protected]


THE BDP PARTY Day 1 | Tuesday, 19 May 2020 Day 2 | Wednesday, 20 May 2020

BDP Week 2020 | Joint Opening Plenary Sessions

Opening Address: China’s Big Leap towards BioPharma 2030– Innovation, Industrialization, Internationalization

Keynote Address: China’s Biopharma Capital Markets – Future Funds and Innovative Financing

Keynote Address: China’s Biologics Facilities for the Future – WuXi’s Story on Technology and Innovation

Venture Capitals’ Roundtable: Show Me the Drug

Manufacturers’ Panel:New Therapies, New Tech and New Investments

• DAL’s New GAMP and Licensing Law – Implementation and oversight

• Biomanufacturing 4.0 – making it happen

• GAMP and Data Integrity requirements

• C&GT – regulation, investment and market opportunities

• BioTech Start ups collaboration hour

• The State-of-Play for CLD&E: Current Landscape & Key Developments

• Novel Advances in CLD Techniques & Technology

• Automation, Digitalization, and Integration of Big Data

• Engineering Host Cell Lines, Genomics & CRISPR in Focus

• Optimising Workflows and Bioprocesses

• China and International Developments and Investments in Biosimilars

• Innovation and Product Differentiation

• Market Access, Marketing and Commercialisation

• Clinical Trials Landscape

End of Conference

AGENDA AT-A-GLANCE

The BDP Party 2020 Committee welcomes all in the

BDP industry to join us along with fellow industry

leaders at this terrific opportunity to network over

dinner and drinks with both local and international

attendees alike.

• Separate registration is required and not limited to

conference participants only

• Dinner will only proceed when we have reached

100 participants

• Payment is only required when the dinner is

confirmed

• Participants list for the dinner will be made

available online once the registration reaches 100

participants


Fee Per Delegate

Early Bird RateRegister & pay before

27 March 2020

Normal RateRegister & pay after

27 March 2020

Start Up Rate

2-Day Conference USD 1,695 USD 1,895 USD 360

Gala Dinner USD 50

Fee Per Delegate

Early Bird RateRegister & pay before

27 March 2020

Normal RateRegister & pay after27 March 2020

Start Up Rate

2-Day ConferenceUSD 903 / CNY 6,000

USD 1,053 / CNY 7,000

USD 360 / CNY 2450

Gala Dinner USD 50

3 EASY WAYS TO REGISTER3 EASY WAYS TO REGISTERContact Miki Kong

Registration Enquiry Email

Website

+65 6508 2477

[email protected]


Informa Connect is a trading name of IBC Asia (S) Pte Ltd.

Connect with us:

REGISTER NOWDelegates who have successfully registered for the event will receive their Online Networking System (ONS) details to connect and network with other attendees nearer to the event date!

*Organisers reserved rights to accept/reject complimentary pass applications submitted, also to request specific job functions as described below. This is to ensure you gain maximum benefit from conference content and networking activities.

Brought to you by:


19–20 MAY 2020Hilton Shanghai Hongqiao, China

Local China CompaniesInternational Companies – Outside China*International Companies with Global HQ Located Outside China

VIP ACCESS

FOR PHARMA

MANUFACTURERS

SPECIAL 1-FOR-1

OFFER FOR CHINA

PHARMACEUTICAL &

BIOTECH COMPANIES*
www.biopharmaproduction.comwww.biopharmaproduction.comhttps://www.biopharmaproduction.com/pricing/

BDP China 2020 Bro€¦ · Yin Nan Po Director, Asia Supply Chain, Amgen, China NEW John Zhang Vice...

Documents

Transcript of BDP China 2020 Bro€¦ · Yin Nan Po Director, Asia Supply Chain, Amgen, China NEW John Zhang Vice...